CoChat

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study

André, T., Tournigand, C., Mineur, L., Fellague-Chebra, R., Flesch, M., Mabro, M., Hebbar, M., Postel Vinay, S., Bidard, F.C., Louvet, C., de Gramont, A. · 2007 · Annals of Oncology
Cited by 39

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdl336

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 23

  1. Jemal, 2002, Cancer statistics, 2002, CA Cancer J Clin, 52, 23, 10.3322/canjclin.52.1.23 · DOI · Paper page
  2. Tournigand, 2006, OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study, J Clin Oncol, 24, 394, 10.1200/JCO.2005.03.0106 · DOI · Paper page
  3. de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
  4. Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 · DOI · Paper page
  5. Maindrault-Goebel, 2000, Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR), Ann Oncol, 11, 1477, 10.1023/A:1026520812351 · DOI
  6. Maindrault-Goebel, 2004, Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer, Ann Oncol, 15, 1210, 10.1093/annonc/mdh305 · DOI
  7. Maughan, 2003, Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC Cr06b randomised trial, Lancet, 361, 457, 10.1016/S0140-6736(03)12461-0 · DOI · Paper page
  8. Raoul, 2005, Chimiothérapie des cancers colorectaux métastatiques: pourquoi ne pas arrêter quand elle marche?, Gastro Clin Biol
  9. Hull, 2000, Cyclooxygenase-2 expression in colorectal cancer liver metastases, Clin Exp Metastasis, 18, 21, 10.1023/A:1026553605636 · DOI
  10. Sano, 1995, Expression of cyclooxygenase-1 and -2 in human colorectal cancer, Cancer Res, 55, 3785
  11. Masferrer, 2000, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, 60, 1306
  12. Oshima, 1996, Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2), Cell, 87, 803, 10.1016/S0092-8674(00)81988-1 · DOI · Paper page
  13. Oshima, 2001, Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor, Cancer Res, 61, 1733
  14. Sheng, 1997, Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2, J Clin Invest, 99, 2254, 10.1172/JCI119400 · DOI · Paper page
  15. Reddy, 2000, Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis, Cancer Res, 60, 293
  16. Yao, 2003, Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice, Cancer Res, 63, 586
  17. Smalley, 1999, Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study, Arch Intern Med, 159, 161, 10.1001/archinte.159.2.161 · DOI · Paper page
  18. Giardiello, 1993, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis, N Engl J Med, 328, 1313, 10.1056/NEJM199305063281805 · DOI · Paper page
  19. Steinbach, 2000, The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis, N Engl J Med, 342, 1946, 10.1056/NEJM200006293422603 · DOI · Paper page
  20. Labianca, 2006, Alternating versus continuous ‘FOLFIRI’ in advanced colorectal cancer (ACC); a randomized ‘GISCAD’ study, Proc Am Clin Oncol, 24, 147s
  21. Alexopoulos, 2006, Continuous versus intermittent chemotherapy in metastatic colorectal cancer, Proc Am Clin Oncol, 24, 166s
  22. Maindrault-Goebel, 2006, GERCOR OPTIMOX 2. A large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study, Proc Am Clin Oncol, 24, 147s
  23. Plantade, 2006, Chemothearpy-free intervals (CFI) in patients with metastatic colorectal cancer, Proc Am Clin Oncol, 24, 166s

Cited by

See all 39

Metadata

Authors
André, T., Tournigand, C., Mineur, L., Fellague-Chebra, R., Flesch, M., Mabro, M., Hebbar, M., Postel Vinay, S., Bidard, F. C., Louvet, C., & de Gramont, A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2007-01
Volume
18
Issue
1
Pages
77-81
ISSN
0923-7534
Cited by
39
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.